pf-04991532
Small moleculeexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01102673)
Timeline
Indications
Mechanism of action
- Hexokinase type IVACTIVATOR
GCK activator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc(NC(=O)[C@H](CC2CCCC2)n2cnc(C(F)(F)F)c2)nc1- Mol. weight
- 396.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2165620 ↗
Also known as
- 6-(3-cyclopentyl-2-(4-trifluoromethyl)-1h-imidazol-1-yl)propanamido)nicotinic acid
- pf-049
- pf-0499132
- pf-04991532
- pf-04991532
- pf-04991532
- pf-04991532
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02117505 | Phase 1 | Apr 1, 2014 | Johnson and Johnson |
| NCT01469065 | Phase 1 | Dec 1, 2011 | Pfizer |
| NCT01469481 | Phase 1 | Nov 1, 2011 | Pfizer |
| NCT01369602 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01370343 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01369277 | Phase 1 | Jun 1, 2011 | Pfizer |
| NCT01336738 | Phase 2 | Jun 1, 2011 | Pfizer |
| NCT01338870 | Phase 2 | Jun 1, 2011 | Pfizer |
| NCT01351129 | Phase 1 | May 1, 2011 | Pfizer |
| NCT01129258 | Phase 1 | Jun 1, 2010 | Pfizer |
| NCT01102673 | Phase 1 | Apr 1, 2010 | Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 10 | 10 | 2 | 2010 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1